IDXG Stock Overview
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
Interpace Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.41|
|52 Week High||US$10.33|
|52 Week Low||US$1.67|
|1 Month Change||-5.49%|
|3 Month Change||-29.12%|
|1 Year Change||-73.66%|
|3 Year Change||-68.31%|
|5 Year Change||-82.91%|
|Change since IPO||-99.89%|
Recent News & Updates
|IDXG||US Healthcare||US Market|
Return vs Industry: IDXG underperformed the US Healthcare industry which returned 14.3% over the past year.
Return vs Market: IDXG underperformed the US Market which returned -13.5% over the past year.
|IDXG Average Weekly Movement||12.2%|
|Healthcare Industry Average Movement||9.0%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.2%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: IDXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: IDXG's weekly volatility (12%) has been stable over the past year.
About the Company
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.
Interpace Biosciences Fundamentals Summary
|IDXG fundamental statistics|
Is IDXG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDXG income statement (TTM)|
|Cost of Revenue||US$23.44m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.02|
|Net Profit Margin||-30.55%|
How did IDXG perform over the long term?See historical performance and comparison
Is IDXG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDXG?
Other financial metrics that can be useful for relative valuation.
|What is IDXG's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IDXG's PS Ratio compare to its peers?
|IDXG PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
GMVD G Medical Innovations Holdings
STRR Star Equity Holdings
CBDS Cannabis Sativa
AMS American Shared Hospital Services
IDXG Interpace Biosciences
Price-To-Sales vs Peers: IDXG is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.4x).
Price to Earnings Ratio vs Industry
How does IDXG's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: IDXG is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Healthcare industry average (1.5x)
Price to Sales Ratio vs Fair Ratio
What is IDXG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.2x|
|Fair PS Ratio||1.2x|
Price-To-Sales vs Fair Ratio: IDXG is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).
Share Price vs Fair Value
What is the Fair Price of IDXG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IDXG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IDXG's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
- Take a look at our analysis of IDXG's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Interpace Biosciences regulatory filings here.
How is Interpace Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDXG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IDXG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IDXG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IDXG's revenue (15.2% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: IDXG's revenue (15.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IDXG's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Interpace Biosciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDXG is currently unprofitable.
Growing Profit Margin: IDXG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IDXG is unprofitable, and losses have increased over the past 5 years at a rate of 20.5% per year.
Accelerating Growth: Unable to compare IDXG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDXG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.9%).
Return on Equity
High ROE: IDXG has a negative Return on Equity (-582.51%), as it is currently unprofitable.
Discover strong past performing companies
How is Interpace Biosciences's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IDXG's short term assets ($13.1M) do not cover its short term liabilities ($16.9M).
Long Term Liabilities: IDXG's short term assets ($13.1M) do not cover its long term liabilities ($19.3M).
Debt to Equity History and Analysis
Debt Level: IDXG's net debt to equity ratio (341%) is considered high.
Reducing Debt: IDXG's debt to equity ratio has increased from 17.5% to 470.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IDXG has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: IDXG is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
What is Interpace Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDXG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDXG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IDXG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Burnell (60 yo)
Dr. Thomas W. Burnell, also known as Tom, Ph D., serves as the President, Chief Executive Officer and Director at Interpace Biosciences, Inc. since December 01, 2020. He serves as the President and Chief E...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD588.35K) is about average for companies of similar size in the US market ($USD770.24K).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
Experienced Management: IDXG's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: IDXG's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.
Interpace Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Interpace Biosciences, Inc.
- Ticker: IDXG
- Exchange: OTCPK
- Founded: 1986
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$10.194m
- Shares outstanding: 4.23m
- Website: https://www.interpace.com
Number of Employees
- Interpace Biosciences, Inc.
- Morris Corporate Center 1
- Building C
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.